Genetic testing IDs some at higher risk for colorectal cancer
The mother of a preschooler is taking advantage of some time to relax, read, and rest. The 36-year-old needs to save the strength she has for what's coming the next day: chemotherapy at Duly Health's cancer infusion center in Hinsdale.
'Chemo's miserable,' she said. 'It's really, really not fun.'
With her husband Patrick by her side, she's undergoing her eighth cycle of chemotherapy. Her hands and feet are covered in 'cold gloves and socks' to reduce two of chemo's most uncomfortable side-effects: cold sensitivity and neuropathy.
Her health ordeal started about one year ago when she came down with norovirus, an intense flu-like sickness that usually passes through the body within about 48-hours. But her abdominal pain lingered much longer.
'About a month after that, I was still having intermittent symptoms stomach pain,' Wozniak said. 'Diarrhea. Something was unsettled. But it seemed like I couldn't have a virus for that long.'
At first, doctors suspected that she had developed an ovarian cyst. 'I still was just feeling – in the morning – a cramping pain,' she said. 'Doubling over. I thought this was just not normal. So, I went to my primary care doctor, and she said this doesn't sound like it's only a cyst, let's send you for a CT. Sure enough, they saw some inflammation in my colon.'
Doctors ordered a colonoscopy and found she had two masses in her colon.
It was cancer.
'I realized right away that everything was going to be different, especially when I had another CT that showed some lesions on my liver, and again I was told, 'oh these could just be fluid filled cysts, nothing,'' she said. 'But it was this kind of intuition that this is not good, and sure enough those came back as cancerous, too.'
The cancer had advanced to stage four, meaning it had spread to other organs. 'Everything you hear about stage 4, you think this is not, this is going to be terminal for me, what am I going to do, I'm 35, I have a three-year-old, so it was pretty devastating and dark for those first few months,' she said.
According to the American Cancer Society, colorectal cancer is the leading cause of cancer death in men younger than 50, and the number two cause of cancer death among women under 50.
'There were a lot of moments where I just cried,' Wozniak said. 'I sat there crying and thinking, 'why is this happening to me?''
Wozniak is one of nearly 20,000 people younger than 50 who were diagnosed with colorectal cancer last year – a dramatic increase and a medical mystery.
'A lot of the media about it is in terms of, like, the environment, what people are eating, lifestyle choices and whatnot,' said Patrick Woulfe, Wozniak's husband. 'I think in Jessica's case that's not necessarily true because hers is due to a genetic condition.'
In Wozniak's case, the cause is clear. She has Lynch Syndrome, an inherited genetic condition associated with an increased risk for colon cancer.
'When I received the genetic test results that almost gave me some piece of mind because I thought, I was blaming myself a lot,' she said. 'Did I eat something that wasn't right? Did I do something to my body? What caused this? The genetic tests made me feel like, in a way, this was inevitable.'
Outside of genetic testing, colorectal cancers can be detected with colonoscopies.
In 2021 the U.S. Preventive Services Task Force lowered the recommended age of screenings from 50 to 45. It's still not young enough to catch many of the new cases.
'I would have rather had a million colonoscopies than deal with this,' Wozniak said. 'A colonoscopy is nothing compared to going through colon cancer.'
Wozniak is sifting through a pile of medical bills, and insurance information, wearing bracelets with the words 'fearless,' 'tough kid,' and her daughter's name. She said she wants to tell her story for her daughter and for everyone else who may have a chance to get screened before they get sick.
'I wish I would have known much sooner, so I could have been screened sooner and caught this sooner,' she said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 hours ago
- UPI
Clinical trial shows promise for new pancreatic cancer vaccine
A small clinical trial suggests a new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back. File Photo by Debbie Hill/UPI | License Photo A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small clinical trial suggests. Pancreatic cancer is one of the most lethal cancers, with a five-year survival rate of about 13%, according to the American Cancer Society. Further, up to 80% of cases return after treatment, the National Institutes of Health says. "If you were to ask me what disease most needs something to prevent recurrences, I'd say this one," Dr. Zev Wainberg, a leader of the trial, told NBC News. He's co-director of the University of California, Los Angeles gastrointestinal oncology program. The experimental vaccine targets KRAS gene mutations, which are found in about 25% of all cancers, the University of Texas MD Anderson Cancer Center says. This includes up to 90% of pancreatic cancers and roughly 40% of colon cancers. While these mutations have long been considered impossible to treat with drugs, researchers are finding new ways to target them. The vaccine, called ELI-002 2P, uses small chains of amino acids called peptides to train the immune system to spot and destroy cells with KRAS mutations. Unlike many cancer vaccines that are custom-made for each patient, this one is designed to be off the shelf, meaning it doesn't require the tumor to be sequenced before it's used, NBC News reported. The Phase 1 study -- reported Tuesday in Nature Medicine -- included 20 people with pancreatic cancer and five with colon cancer. All had KRAS mutations and had already undergone surgery and chemotherapy. Blood tests after surgery showed microscopic evidence of residual disease - cancer cells too small to see on scans. These leftover cells can cause the cancer to spread and return. Post-surgery, participants received up to six priming doses of the vaccine, with 13 also getting booster shots. In all, the process took six months. Here's what the results showed: 85% (21 of 25 participants) had an immune response to the KRAS mutations. About two-thirds of those had a strong enough response to help clear lingering cancer cells. Nearly 70% developed immunity to other tumor targets not included in the vaccine. A few "super-responders" had exceptionally strong immune reactions and the best outcomes. In the pancreatic cancer group, patients survived for an average of 29 months, staying recurrence-free for more than 15 months after vaccination. "That far exceeds the rates with resectable [surgically removable] cancers," Wainberg said. Cancer vaccines have been difficult to create because cancer cells share many proteins with healthy cells, making safe targets hard to find. Advances in mRNA technology and faster gene sequencing are now making more effective cancer vaccines possible. The peptides in this vaccine also have a unique "tail" that helps them stay in lymph nodes, where immune cells are activated -- a feature past peptide vaccines didn't have, said Stephanie Dougan, an associate professor at Dana-Farber Cancer Institute in Boston, who was not involved in the study. More research is needed to confirm the findings, and a Phase 2 trial is now underway to compare the vaccine with standard care. "The fact that the long-term survival really correlated with T-cell response suggests that the vaccine caused this," Dougan said, referring to the specific immune cells activated by the vaccine. "The idea that you can target KRAS is really exciting." More information The Mayo Clinic has more on pancreatic cancer. Copyright © 2025 HealthDay. All rights reserved.
Fox News
a day ago
- Fox News
Colorectal cancer may cause these 4 hidden warning signs, experts say
Colorectal cancer rates have soared among younger Americans, new research has found — and there might not always be obvious symptoms. The lifetime risk of developing colorectal cancer (CRC) is one in 24 for men and one in 26 for women, according to the American Cancer Society. It is the third-leading cause of cancer-related deaths in men and the fourth in women, but is the second most common cause when the numbers for men and women are combined. While there may be no symptoms of CRC before diagnosis, especially in the early stages, the following signs and symptoms should not be overlooked, experts say. According to the Colorectal Cancer Alliance, some symptoms of the disease can be similar to other causes, like hemorrhoids, infection or irritable bowel syndrome (IBS). But a change in bowel habits — including diarrhea, constipation, narrow stools or feeling like your bowels are full even after a movement — can be a sign of CRC. Fight Colorectal Cancer, a leading patient advocacy group, noted on its website how bowel movements can change due to diet, infections, medications and other medical issues. A change in bowel movement schedule or stool appearance could also signal CRC. Fight CRC recommends calling a doctor if your stool is consistently abnormal, if you have sudden urges to pass stool but can't control it, if the stool is black, clay-colored, red or white, or if there is mucus or pus in the stool. Skinny, thin or pencil-like stool may also indicate an obstruction in the colon, like a tumor, but can also be caused by other harmless, temporary conditions. Persistent discomfort in the abdomen is another CRC symptom, the Colorectal Cancer Alliance reported on its site. This can include feelings of pain, nausea, cramping, bloating or feeling unusually full, even after not eating much. Severe, "knife-in-my-stomach type" abdominal pains warrant a visit to the emergency room, Fight CRC instructed — but even mild pains shouldn't be taken lightly. Blood in the stool, toilet or when wiping with toilet paper can be a major sign of colorectal cancer. Fight CRC stressed that any amount of rectal bleeding is not normal and should be brought to a doctor's attention for proper diagnosis. Since blood in the stool is a common symptom, Fight CRC instructed paying attention to where the blood is found, how often it occurs and whether bowel movements are painful. Unexplained weight loss can sometimes be caused by cancer and should be brought to the attention of a doctor, according to the Colorectal Cancer Alliance. Weight loss is the result of cancer cells "consuming the body's energy" as they multiply, Fight CRC explained, as the immune system expends more energy to fight and destroy cancer cells. This can also lead to feeling fatigue, weakness or shortness of breath. For more Health articles, visit These symptoms may also be a sign of anemia, which can develop from bleeding somewhere inside the body, like from a cancerous tumor. Weight loss can also be caused by a tumor blocking the colon or intestinal tract, which prevents proper nutrient absorption.
New York Post
a day ago
- New York Post
Beware these 5 signs of a ‘highly invasive' brain cancer — patients typically survive only 15 months
That stinks! A 57-year-old UK father of four recently made headlines when he revealed the bizarre clue that preceded his Stage 4 glioblastoma diagnosis — a 'strange sweet caramel smell.' 'We didn't think much of it,' said Costa Fantis's 27-year-old son, Antonio. 'We definitely didn't know it was a symptom of something so serious.' Before two-time Grammy winner Michael Bolton, 72, was diagnosed with glioblastoma in 2023, he experienced confusion, balance issues, nausea and severe headaches. 5 Michael Bolton performs on stage in 'The Wonderful World of Disney: Magical Holiday Celebration,' which taped in November 2023. He was diagnosed with glioblastoma the following month. ABC via Getty Images The tumor, which occurs when supportive cells in the brain grow and divide uncontrollably, is extremely aggressive and deadly. Most patients survive only 14 to 16 months after diagnosis. 'What makes glioblastoma particularly difficult to treat is its highly invasive nature — it spreads microscopic cancer cells deep into surrounding brain tissue, making it impossible to remove completely with surgery,' Dr. Joseph Georges, a neurosurgeon based in Phoenix, told The Post. Georges shares five early glioblastoma warning signs — and how a specialized cell therapy may prolong patient lives. What are the risk factors for glioblastoma? About 14,500 new glioblastoma cases are diagnosed annually in the US. 5 Dr. Joseph Georges, a neurosurgeon based in Phoenix, reveals five early glioblastoma warning signs — and how a specialized cell therapy may prolong patient lives. The average age of diagnosis is around 64 — the cancer tends to affect adults 45 to 70 years old. Exposure to ionizing radiation as part of radiation therapy for other cancers and certain genetic disorders, such as Turcot syndrome and Lynch syndrome, can increase glioblastoma risk. However, most cases 'occur spontaneously in individuals without risk factors,' said Georges, an assistant professor of neurosurgery at the University of Arizona College of Medicine and Banner University Medical Center-Phoenix. What are the symptoms? Symptoms depend on the tumor's location within the skull. They may include headaches, confusion, seizures, speech difficulty or weakness on one side of the body, Georges said. In Bolton's case, his daughters noticed unusual behavior during a family bowling night in the fall of 2023. 5 This is a scan of a grade 4 glioma brain tumor that's about the size of a tennis ball. Caters News Agency He had bowled out of turn and fallen out of his chair. He was diagnosed a few weeks later. Fantis's tumor appears to have developed in the temporal lobe, which plays a crucial role in processing smells. How is it diagnosed? The tumor can be identified with a CT scan or MRI, and the diagnosis confirmed with a tissue biopsy. 'Several factors influence how long a person might live with glioblastoma,' Georges said, 'including their overall health, neurological function at diagnosis, age and how well they respond to treatments such as surgery, radiation and chemotherapy.' The molecular characteristics of the tumor — like whether it has mutations — can affect the prognosis. How is glioblastoma treated? Metastatic brain tumors — tumors that start elsewhere in the body and spread to the brain — tend to form masses that are better defined than glioblastomas and that can be surgically removed more easily. 'Glioblastoma's diffuse growth pattern, genetic complexity and resistance to standard treatments make it one of the most challenging brain tumors to treat,' Georges noted. 'Complete removal is usually not achievable due to the tumor's infiltrative nature.' 5 Glioblastomas can be identified with a CT scan or MRI, and the diagnosis confirmed with a tissue biopsy. angkhan – Surgery is often followed by radiation therapy to eliminate residual tumor cells and delay progression and chemotherapy to enhance the effectiveness of radiation. Despite this multi-pronged strategy, Georges admitted that 'glioblastoma generally has a poor prognosis due to its aggressive biology and treatment resistance.' How can DOC1021 help? Georges said he has seen better outcomes with an individualized approach. He was the principal investigator of a Phase 1 clinical trial evaluating Dubodencel, also known as DOC1021, which harnesses the power of the patient's special immune cells, called dendritic cells. The cells are exposed to the unique antigens of the tumor outside the body. 'Once trained, the cells are multiplied and then returned to the patient, where they help the immune system launch a targeted attack against the cancer,' Georges said. 'Because this approach uses the patient's own immune cells and doesn't require genetic modification, it offers a highly personalized and comprehensive way to address the complexity and variability of glioblastoma.' 5 These before-and-after brain scans show glioblastoma resolution with DOC1021. The Food and Drug Administration granted fast-track designation to DOC1021, developed by Diakonos Oncology, to treat glioblastoma and pancreatic cancer. Some patients in the DOC1021 Phase 1 trial are approaching 24 to 36 months of survival. 'Early clinical results from the trial showed a 12-month overall survival rate of 88%, markedly higher than the approximately 60% typically seen with standard of care,' Georges said. New Jersey resident Pamela Goldberger, 65, underwent brain surgery, six weeks of chemotherapy and radiation, six weeks of the cell therapy and a year of chemo maintenance as part of the DOC1021 Phase 1 trial. Now, she is back to playing tennis several times a week 2½ years after her diagnosis. 'I'm living my best life right now, and I'm not restricted by not being able to do anything that I would want to do,' she recently told Fox News Digital. The Phase 2 clinical trial is underway — it's expected to be available at 20 US sites.
